Locoregional IL-13Rα2-targeted CAR T cell therapy, including intratumoral and intraventricular injections, has shown promise for high-grade gliomas, suggesting that locoregional delivery may mitigate the need for lymphodepletion [170]. Here, IL13RA2 is linked to central nervous system cancer.